The association between multiple sclerosis and pain medications

Burkill, Sarah; Montgomery, Scott; Kockum, Ingrid; Piehl, Fredrik; Strid, Pernilla; Hillert, Jan; Alfredsson, Lars; Olsson, Tomas; Bahmanyar, Shahram

doi:10.1097/j.pain.0000000000001429

Cited by 14 publications

(19 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At lik ta me ty ri me neu ro pa ti nis skaus mas pa si reið kë dau giau nei pu sei ti ria mø jø, daþ niau siai, kaip mi në ta, bu vo apa ti në se ga lû në se, daþ niau sias po bû dis -de gi nan tis. Lite ra tû ros duo me ni mis, neu ro pa ti nis skaus mas ran da mas dau giau nei pu sei ti ria mø jø ir yra daþ nes nis, ser gant progre suo jan èio mis li gos for mo mis, taip pat daþ nes nis jaunes niems þmo nëms [5,15,16]. Li te ra tû ro je nu ro do mas neu ro pa ti nio skaus mo po bû dis daþ niau siai yra elek tros sro vës pli ti mo, ant ro je vie to je -de gi nan tis [17].…”

Section: Rezultatø Aptarimasunclassified

“…Kuo di des nis skaus mas, tuo di des nis ir spastið ku mas. Tai pa ro do, kad neu ro pa ti nis skaus mas ir spastið ku mas yra glau dþiai su si jae: ga lû në je, ku rio je yra di desnis spas tið ku mas, pro gre suo ja ir neu ro pa ti nis skaus mas [16,17].…”

Section: Rezultatø Aptarimasunclassified

“…Li te ra tû ros duo me ni mis, spas tið ku mas ga li su kel ti skaus mà. Ðià hi pote zae áro dë ir mû sø at lik tas ty ri mas: neu ro pa ti nis skaus mas bu vo ste bi mas to se pa èio se ga lû në se, kur bu vo nu sta ty tas spas tið ku mas [14,[16][17][18]. Ðiai hi po te zei (spas tið ku mas turi áta kos neu ro pa ti niui skaus mui at si ras ti) pa tvir tin ti rei këtø dau giau ið nag ri në ti spas tið ku mo ir neu ro pa ti nio skausmo at si ra di mo me cha niz mus, la biau ið si aið kin ti, ka da at sira do spas tið ku mas ir ka da -skaus mas, ka d bû tø ga li ma pati ki miau pa tvir tin ti ar pa neig ti ðià sà sa jà.…”

Section: Rezultatø Aptarimasunclassified

“…Spas tið ku mo ir neu ro pa ti nio ry ðio ra di mas ga li pa dë ti pa ge rin ti ser gan èiø jø IS gy ve ni mo ko ky bae, nes pa cien tai, jau èian tys spas tið ku mà ir neu ro pa ti ná skaus mà, daþ niau skun dþia si nuo var giu ir dep re si ja. Ðio ty ri mo me tu ne bu vo ver tin ta pa cien tø gy ve ni mo ko ky bë, ta èiau, rem da mie si lite ra tû ra, ga li me teig ti, kad pa cien tai, ku rie skun dë si spastið ku mu ir neu ro pa ti niu skaus mu, daþ niau skun dë si bloges ne gy ve ni mo ko ky be, daþ nes niu nuo var giu ir blo ga nuo tai ka [14,16,18]. Tai gi, at ra dae ðià sà sa jà, ga lë si me skir ti efek ty ves ná gy dy mà ir pa gel bë si me pa cien tams kasdie nia me jø gy ve ni me.…”

Section: Rezultatø Aptarimasunclassified

See 3 more Smart Citations

Spastiškumo sąsajos su neuropatiniu skausmu pacientams, sergantiems išsėtine skleroze

Afanasjeva¹,

Balnytė²

2019

View full text Add to dashboard Cite

Lietuvos sveikatos mokslø universitetas, Medicinos fakultetas **Lietuvos sveikatos mokslø universiteto ligoninë Kauno klinikos, Neurologijos klinika ÁVADASIð së ti në skle ro zë (IS) -tai lë ti në uþ de gi mi në au to imu ni në de mie li ni zuo jan ti cen tri nës ner vø sis te mos li ga, pa si reiðkian ti re ci dy vuo jan èiais ar ba nuo lat pro gre suo jan èiais neu ro lo gi niø funk ci jø su tri ki mo simp to mais, il gai niui suke lian èiais ne ga lià. Daþ niau siai ser ga jau ni þmo nës [1][2][3]. Spas tið ku mas yra vie na ið ne ága lu mà su ke lian èiø kom pli -NEUROLOGIJOS SEMINARAI • ISSN 1392-3064 / eISSN 2424-5917 67 ORIGINALUS MOKSLINIS DARBAS © Neurologijos seminarai, 2019. Open Ac cess. This ar ti cle is dis trib uted un der the terms of the Cre ative Com mons At tri bu tion 4.0 Inter na tional Li cense CC-BY 4.0 (http://creativecommons.org/licenses/by/4.0/), which per mits un re stricted use, dis tri bu tion, and re produc tion in any me dium, pro vided you give ap pro pri ate credit to the orig i nal au thor(s) and the source, pro vide a link to the Cre ative Com mons li cense, and in di cate if changes were made. Neurologijos seminarai 2019; 23(80): 67-… 70San trau ka. Áva das. Ið së ti në skle ro zë (IS) -tai lë ti në uþ de gi mi në au to imu ni në de mie li ni zuojan ti cen tri nës ner vø sis te mos li ga. Spas tið ku mas yra vie na ið ne ága lu mà su ke lian èiø kom plika ci jø pa cien tams, ser gan tiems ðia li ga, ir ga li tu rë ti áta kos neu ro pa ti nio skaus mo at si ra dimui, ku rie kar tu dar la biau su trik do pa cien to kas die nae veik là.Ti ria mie ji ir ty ri mo me to dai. Bu vo ti ria mi pa cien tai, ser gan tys IS. Ser gan èiø jø IS ne ga lia ver tin ta nau do jant ið plës ti nae ne ga lios ver ti ni mo ska lae (EDSS), spas tið ku mas -nau do jant mo di fi kuo tà As hworth spas tið ku mo ska lae, neu ro pa ti nis skaus mas -nau do jant neu ro pa ti nio skaus mo diag nos ti kos klau si my nà (DN4).Re zul ta tai. Ty ri me da ly va vo 59 pa cien tai. Ti ria mø jø gru pae su da rë 39 mo te rys ir 20 vy rø. Ti ria mie ji sir go re ci dy vuo jan èia re mi tuo jan èia -52 pa cien tai (88,1 %), pro gre suo jan èia -7 (11,9 %) IS li gos for mo mis. Ly gi nant li gos for mas, di des nis ne ga lios laips nis bu vo nu sta tytas ser gan tie siems pro gre suo jan èia li gos for ma -6,36 ± 1,38, o ser gan tie siems re ci dy vuo janèia re mi tuo jan èia li gos for ma -4,38 ± 1,4 (p = 0,001). Spas tið ku mas nu sta ty tas 35 (59,3 %) pa cien tams, ser gan tiems IS. Jo lo ka li za ci ja (N = 35): per al kû nës sà na rá -2 (5,71 %), ke lio sà na rá -27 (77,14 %), al kû nës ir ke lio sà na rá -6 (17,15 %). Neu ro pa ti nis skaus mas nu sta tytas 33 pa cien tams (55,9 %), skaus mo lo ka li za ci ja: vir ðu ti në se ga lû në se -5 (15,15 %), apa tinë se ga lû në se -23 (69,7 %), abie jo se ga lû në se -5 (15,15 %). Mo te rims (N = 39; 61,54 %) spas tið ku mas bu vo nu sta to mas daþ niau nei vy rams (N = 20; 55 %) (p = 0,42). Neu ro pa ti nio skaus mo po bû dis: de gi nan tis -18 (30,5 %), pri me na s...

show abstract

Section: Rezultatø Aptarimasunclassified

See 2 more Smart Citations

Spastiškumo sąsajos su neuropatiniu skausmu pacientams, sergantiems išsėtine skleroze

Afanasjeva¹,

Balnytė²

2019

View full text Add to dashboard Cite

show abstract

“…Individuals with MS experience a wide variety of symptoms, one of which is pain. Recently, we reported that MS patients are affected by pain, in particular neuropathic pain, to a greater extent than the general population through considering prescribed pain medications as a proxy for a pain diagnosis (1). The neuropathic pain in MS likely stems from the disease inherent lesions in the CNS (2).…”

Section: Introductionmentioning

confidence: 99%

The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Murine models have demonstrated that the major histocompatibility complex (MHC) is associated with pain-like behavior in peripheral nerve injury, however, the same association has not been shown when considering injury to the central nervous system (CNS), which more closely mimics the damage to the CNS experienced by MS patients. Previous research has indicated the DQB1 * 03:02 allele of the class II HLA genes as being associated with development of neuropathic pain in persons undergoing inguinal hernia surgery or with lumbar spinal disk herniation. Whether this HLA allele plays a part in susceptibility to pain, has not, as far as we are aware, been previously investigated. This study utilizes information on DQB1 * 03:02 alleles as part of the EIMS, GEMS, and IMSE studies in Sweden. It also uses register data for 3,877 MS patients, and 4,548 matched comparators without MS, to assess whether the DQB1 * 03:02 allele is associated with prescribed pain medication use, and whether associations with this genotype differ depending on MS status. Our results showed no association between the DQB1 * 03:02 genotype and pain medication in MS patients, with an adjusted odds ratio (OR) of 1.02 (95% CI 0.85-1.24). In contrast, there was a statistically significant association of low magnitude in individuals without MS [adjusted OR 1.18 (95% CI 1.03-1.35)], which provides support for HLA influence on susceptibility to pain in the general population. Additionally, the effect of zygosity was evident for the non-MS cohort, but not among MS patients, suggesting the DQB1 * 03:02 allele effect is modified by the presence of MS.

show abstract

Sensory and pain modulation profiles of ongoing central neuropathic extremity pain in multiple sclerosis

Šrotová

Kočica

Vollert

et al. 2020

European Journal of Pain

View full text Add to dashboard Cite

Background Central neuropathic extremity pain (CNEP) is the most frequent type of pain in multiple sclerosis (MS). The aim of the present study was to evaluate sensory and pain modulation profiles in MS patients with CNEP. Methods In a single‐centre observational study, a group of 56 CNEP MS patients was compared with 63 pain‐free MS patients and with a sex‐ and age‐adjusted control group. Standardized quantitative sensory testing (QST) and dynamic QST (dQST) protocols comprising temporal summation and conditioned pain modulation tests were used to compare sensory profiles. Results Loss‐type QST abnormalities in both thermal and mechanical QST modalities prevailed in both MS subgroups and correlated significantly with higher degree of disability expressed as Expanded Disability Status Scale (EDSS). Comparison of sensory phenotypes disclosed a higher frequency of the ‘sensory loss’ prototypic sensory phenotype in the CNEP subgroup (30%) compared with pain‐free MS patients (6%; p = .003). Conclusion The role of aging process and higher lesion load in the spinothalamocortical pathway might be possible explanation for pain development in this particular ‘deafferentation’ subtype of central neuropathic pain in MS. We were unable to support the role of central sensitization or endogenous facilitatory and inhibitory mechanisms in the development of CNEP in MS. Significance This article presents higher prevalence of the ‘sensory loss’ prototypic sensory phenotype in multiple sclerosis patients with central extremity neuropathic pain compared to pain‐free patients. Higher degree of disability underlines the possible role of higher lesion load in the somatosensory pathways in this particular ‘deafferentation’ type of central neuropathic pain.

show abstract

The association between multiple sclerosis and pain medications

Cited by 14 publications

References 145 publications

Spastiškumo sąsajos su neuropatiniu skausmu pacientams, sergantiems išsėtine skleroze

Spastiškumo sąsajos su neuropatiniu skausmu pacientams, sergantiems išsėtine skleroze

The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis

Sensory and pain modulation profiles of ongoing central neuropathic extremity pain in multiple sclerosis

Contact Info

Product

Resources

About